Outlook for the contract manufacturing industry following the growing biologics pipeline
The recent years have portrayed the renaissance in the domain of biologics, as pharmaceutical industry has once again gained attention towards the production of bioproducts. In fact, in 2019, a total of 28 biopharmaceutical products (including monoclonal antibodies, recombinant proteins and gene therapies) were approved in the US.
Related Bookmarks
- Digital Biomarkers: Is Efficient Remote Monitoring of COVID-19 Patients Primary Reason for Incessant
- Artificial Intelligence in Drug Discovery � Could help Reduce Significant Capital and Time Required
- Drug-Drug and Drug-Food Interactions
- A Rare Pulmonary Infectious Disease: Nocardiosis
- Acute MI after High-Dose Recreational Nitrous Oxide Use
- 10 Secrets to Living a Happier Life
- Why You Hate: The Science Behind Why We Love to Hate
- How do you get rid of anger and hate?
- Thinking About Plastic Surgery? First Know About It
- Is A 30 Minute Personal Training Session Enough
Recent Profiles
Financial Driven Research
James
Sakshi
Xx88
Data Result China
Inarastayle
Cổng Game 8us
Axiscolleges
Topbet
Call4up